We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ABVX

Price
5.97
Stock movement down
-0.08 (-1.32%)
Company name
Abivax SA American Depositary Shares
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
451.17M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-55.94%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ABVX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

FINANCIALS

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open6.18
Daily high6.19
Daily low5.88
Daily Volume334K
All-time high15.89
1y analyst estimate97.00
Beta0.07
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date8 Sep 2025

Downside potential

Loading...
Downside potential data
ABVXS&P500
Current price drop from All-time high-62.43%-3.04%
Highest price drop-67.46%-56.47%
Date of highest drop8 Apr 20259 Mar 2009
Avg drop from high-28.85%-11.04%
Avg time to new high13 days12 days
Max time to new high290 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABVX (Abivax SA American Depositary Shares) company logo
Marketcap
451.17M
Marketcap category
Small-cap
Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Employees
69
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

September 9, 2024

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...